A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Recruiting now · Phase 1
Conditions studied: Multiple Myeloma, Myeloma, Myeloma Multiple
In brief
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Key facts
- Study ID
- NCT05651932
- Run by
- K36 Therapeutics, Inc.
- People needed
- 165
- Starts
- 2023-02-22
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2026-06-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic — San Francisco, California, United States (enrolling)
- Mayo Clinic Hospital - Florida — Jacksonville, Florida, United States (enrolling)
- The Winship Cancer Institute of Emory University — Atlanta, Georgia, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Mayo Clinic - Transplant Center - Rochester — Rochester, Minnesota, United States (enrolling)
- Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States (enrolling)
- Atrium Health, Levine Cancer Institute — Charlotte, North Carolina, United States (enrolling)
- Duke University Hospital — Durham, North Carolina, United States (enrolling)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center — Dallas, Texas, United States (enrolling)
- University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital) — Toronto, Ontario, Canada (enrolling)
- Universitaire de Lille — Villeneuve-d'Ascq, France, France (enrolling)
- Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu — Nantes, France (enrolling)
- Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers) — Poitiers, France (enrolling)
- Institut Universitaire du Cancer de Toulouse - Oncopole — Toulouse, France (enrolling)
- Clínica Universidad de Navarra — Pamplona, Navarre, Spain (enrolling)
- Hospital ClÃ-nic de Barcelona — Barcelona, Spain (enrolling)
- Hospital Universitario 12 de Octubre — Madrid, Spain (enrolling)
- Instituto de Investigacion Biomedica de Salamanca (IBSAL) — Salamanca, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.